BRAIN Biotech AG (0RFI.L)
| Previous close | 7.60 |
| Open | 7.60 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 7.60 - 7.60 |
| 52-week range | 7.60 - 7.60 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 137.495M |
| Beta (5Y monthly) | 1.44 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.37 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
BRAIN Biotech publishes first ESG and Sustainability Report
DGAP-News: BRAIN Biotech AG / Key word(s): SustainabilityBRAIN Biotech publishes first ESG and Sustainability Report 20.06.2022 / 08:00 The issuer is solely responsible for the content of this announcement.BRAIN Biotech publishes first ESG and Sustainability ReportZwingenberg, June 20, 2022 – BRAIN Biotech AG has published its first ESG and sustainability report. The company, which already directly addresses at least five UN Sustainable Development Goals (SDGs) with its products and solutions, s
- EQS Group
BRAIN Biotech AG: Prof. Dr. Bernhard Hauer leaves Supervisory Board of BRAIN Biotech AG for personal reasons
DGAP-News: BRAIN Biotech AG / Key word(s): PersonnelBRAIN Biotech AG: Prof. Dr. Bernhard Hauer leaves Supervisory Board of BRAIN Biotech AG for personal reasons 30.05.2022 / 09:00 The issuer is solely responsible for the content of this announcement.Prof. Dr. Bernhard Hauer leaves Supervisory Board of BRAIN Biotech AG for personal reasonsZwingenberg, 30.05.2022 – Professor Dr. Bernhard Hauer has informed the Chairman of the Supervisory Board of BRAIN Biotech AG that he wishes to resign from his
- EQS Group
BRAIN Biotech AG: Ongoing Dynamic Sales Development and Rising Profitability, 6M Reporting
DGAP-News: BRAIN Biotech AG / Key word(s): Half Year Results/Half Year ReportBRAIN Biotech AG: Ongoing Dynamic Sales Development and Rising Profitability, 6M Reporting 30.05.2022 / 07:30 The issuer is solely responsible for the content of this announcement.BRAIN Biotech AG: Ongoing Dynamic Sales Development and Rising Profitability, 6M Reporting Very positive growth trend confirmed by 20% organic expansion in Q2 Significant improvement in profitability, adjusted EBITDA positive Full fiscal year
